Why Axsome Therapeutics, Inc. (AXSM) Stock Fell 5.8% on Nov 2, 2026
What happened
Axsome Therapeutics reported Q3 2026 earnings today, beating revenue estimates but posting a net loss, according to Zacks and the company's earnings release via Globe Newswire. The stock fell 11.63% to $127.64, a sharp intraday decline following the mixed results announcement.
Earnings call details and management guidance on cash runway and profitability timeline; next scheduled earnings event is November 9, 2026 (consensus EPS estimate −$0.42).
Other developments that session
Axsome Therapeutics, Inc. (AXSM) reported EPS of −$0.25 vs. consensus estimate of −$0.63, beating expectations by 60.6% on 2026-11-02.
Axsome Therapeutics, Inc. (AXSM) filed a new 8-K on November 2, 2026. The filing content was not disclosed in available sources.
AXSM reported Q3 loss of $0.25/share, beating consensus estimate of $0.69/share loss.
Frequently asked questions
Why did Axsome Therapeutics, Inc. (AXSM) stock fall on Nov 2, 2026?
Axsome Therapeutics reported Q3 2026 earnings today, beating revenue estimates but posting a net loss, according to Zacks and the company's earnings release via Globe Newswire. The stock fell 11.63% to $127.64, a sharp intraday decline following the mixed results announcement.
How much did AXSM stock fall on Nov 2, 2026?
AXSM fell 5.8% during the Nov 2, 2026 trading session.